Actively Recruiting
Beta-Adrenergic Modulation of Drug Cue Reactivity
Led by University of Oklahoma · Updated on 2026-04-28
80
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
Sponsors
U
University of Oklahoma
Lead Sponsor
O
Oklahoma State University Center for Health Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
CONDITIONS
Official Title
Beta-Adrenergic Modulation of Drug Cue Reactivity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Generally healthy
- Age between 21 and 60 years
- Right-handed based on a three-item scale
- Daily smoker of at least 5 cigarettes delivering 0.5 mg nicotine
- Smoking regularly for at least 1 year with stable smoking for the past 6 months
- Afternoon expired Carbon Monoxide concentration of at least 6 ppm and/or morning urinary cotinine above 100 ng/ml
- Identification of at least 4 different smoking locations used in a typical week
- Able to read and understand English
You will not qualify if you...
- Unable to attend all required sessions
- Significant health problems preventing active participation
- Conditions making MRI unsafe (e.g., pacemaker, weight, or body shape issues)
- Current use of psychoactive medications or drugs
- Positive breath alcohol concentration
- Pregnant, breastfeeding, or planning pregnancy during the study (females)
- Vision problems not correctable with contacts or glasses
- Regular use of smokeless tobacco, smoking cessation medications, or other nicotine products
- Current use of beta-adrenergic or other blood pressure medications
- Systolic blood pressure below 90 mmHg or diastolic below 60 mmHg (sitting or standing)
- Abnormal EKG
- Severe anemia
- Electrolyte imbalance affecting blood pressure
- Any contraindications for propranolol or nicotine patch (e.g., cardiovascular disease, asthma, allergies, diabetes)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hardesty Center for Clinical Research and Neuroscience
Tulsa, Oklahoma, United States, 74136
Actively Recruiting
Research Team
J
Jason A Oliver, PhD
CONTACT
I
Isabel Brush, B.A.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here